Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

Milestone achievement triggers $15 million payment from collaborator

GlaxoSmithKline

CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced the initiation of a pivotal Phase 3 clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes. As a result of the initiation of patient dosing in DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), Tolerx will receive a $15 million milestone payment from GlaxoSmithKline.

DEFEND is a randomized, placebo controlled Phase 3 trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers in North America and Europe. The trial will evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will reduce the amount of administered insulin required to control blood glucose levels by inhibiting the destruction of beta cells. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, and a reduction in long-term disease complications in established type 1 diabetics in the Diabetes Control and Complications Trial (DCCT).

"We are excited to have dosed the first patient in DEFEND and look forward to continued patient enrollment in this Phase 3 clinical trial. The initiation of DEFEND represents the culmination of a methodical, dose-ranging development plan, including the successful outcome from an end-of-Phase 2 meeting at FDA. We believe otelixizumab has the potential to provide an important new treatment option for patients with newly dia
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Calif. , Aug. 27, 2014  After the ... and Personal Injury billing solution for medical practices ... positive response toward the new software. "The ... Sandy Thompson . "The sheer number of demos ... true the need was for these types of software ...
(Date:8/27/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global ... participating in the Morgan Stanley 2014 Global Healthcare Conference ... New York , on Tuesday, September 9, 2014.  ... will be presenting at 9:10 a.m. Eastern Time.  ... join Mr. Dvorak for the Q&A session. ...
(Date:8/27/2014)... 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ), ... , today announced the results of the Company,s 2014 Annual General ... Beijing , PRC. The required quorum, a majority of ... The Company,s shareholders approved the following proposals:  , The ... Simon Anderson , Kenneth Lee and Meng ...
Breaking Medicine Technology:Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... 2011 Ingenious Med, the leading platform for automated ... now available on the App Store for iPhone, iPod ... part of the company,s presence at the Hospital Information ... Ingenious Med,s 9,000 users to access the charge and ...
... Feb. 17, 2011 NexBio, Inc. announced the presentation ... a Patient after Allogeneic Stem Cell Transplantation" at the ... February 17-21 in Honolulu, Hawaii.  The data was presented ... General Hospital and Harvard Medical School. Parainfluenza ...
Cached Medicine Technology:HIMSS11: Ingenious Med Launches Billing and Data Capture App for iPhone, iPod touch and iPad 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 2NexBio’s DAS181 (Fludase®*) Improved Symptoms in a Severely Immunocompromised Patient with Parainfluenza Pneumonitis 3
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the first ... Digital O.R. at Aspirus Wausau Hospital, in Wausau, WI. ... rooms will be Buzz, a centralized surgical hub for ... planning, navigation, imaging and communications connectivity. , Buzz ... and hardware all controlled from the full HD 42” ...
(Date:8/27/2014)... UNIWIGS, one of the leading purveyors of real and synthetic ... sales on all its products, for the coming Labor Day. , ... UniWigs hair products in two ways: when they spend ... a coupon code LABOR10; while when they spend more than $299, ... deal which coupon code is needed when securely checkout, there are ...
(Date:8/27/2014)... Hepatocellular carcinoma (HCC) is the second leading cause ... are due to the difficulty in treating this ... epirubicin, cisplatin, 5-fluorouracil, etoposide or combinations therein. This ... are not able to reach in a sufficient ... that are not harmful to the rest of ...
(Date:8/27/2014)... Fluorochemicals are synthetically produced chemicals, which repel water ... and chemical conditions in industrial processing. These characteristics ... and products, such as coatings for food paper ... that they are difficult to break down and ... fluorochemicals have known correlations with harmful health effects, ...
(Date:8/27/2014)... 27, 2014 DISCcert has scheduled its ... place Sept 10th, 17th, 24th, and Oct 1st from ... receive a certification seal that will allow them to ... consists of four weekly one-hour webinar sessions. In between ... are offered individual coaching time. , Trainers, participating ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 2Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 3Health News:Online DISC Certification Webinar Series to Begin Sept 10 Announces DISCcert 4
... researcher Dr. Daniel Von Hoff, a member of ... in-depth look at the "lost opportunity" in phase ... companies use the phase I trial to evaluate ... advocates that it can also provide valuable efficacy ...
... have made several, subtle changes in the structure of a ... according to a study published in a December edition of ... have profound implications for the treatment of hemophilia, the inherited ... Americans. , In most cases, hemophilia is ...
... those with lupus, rheumatoid arthritis , , MONDAY, Dec. 22 ... cells, but these cells stay in an "off" state, ... the body cause autoimmune diseases such as lupus and ... adults are true precursors of the self-attacking immune cells ...
... common this time of year , , MONDAY, Dec. 22 ... holidays this year, with many people both blue and ... jobless rate in three decades and a jackknifing stock market. ... often during the winter months not only because of the ...
... fresh start for career-building in today,s tough economic times. The ... professions. , ... (PRWEB) December 22, ... a recruiting campaign targeting career changers and other potential students. ...
... 2008, Cambridge, UK Scientists report that human gene mutations ... Disease, a fatal nervous system disorder that begins during childhood. ... (DMM), dmm.biologists.org , describes how the extent of ... in humans. ,The initial, milder symptoms of Batten ...
Cached Medicine News:Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 2Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 3Health News:Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials' 4Health News:Redesigned protein accelerates blood clotting 2Health News:Redesigned protein accelerates blood clotting 3Health News:Redesigned protein accelerates blood clotting 4Health News:Blue and Broke for the Holidays 2Health News:Blue and Broke for the Holidays 3Health News:Blue and Broke for the Holidays 4Health News:Parker College of Chiropractic Education Launches Recruiting Campaign for Career Changers and Potential Students 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: